# China's in-vivo gene-editing pipeline reaches the clinic
> Huida claims first CRISPR injected into a human brain; YolTech's LNP edit becomes China's first in-vivo gene-editing drug in trials

**Meta:** type: event · date: 2026-06-10 · heads: 长远之局, 生活如何改变 · 7 takes · 3 lenses · 2 regions

## Summary

China's in-vivo [gene-editing](/zh/entity/gene-editing) pipeline reached the clinic in the first half of 2026. [Huida Gene Therapeutics](/zh/entity/huida) reported clinical data from a [CRISPR](/zh/entity/crispr) RNA-editing therapy injected directly into the human brain to treat MECP2 duplication syndrome, billed in Chinese pharma press (医药魔方) as a world first for in-brain CRISPR delivery and the second CRISPR RNA-editing therapy globally to enter human testing. Separately, [YolTech](/zh/entity/yoltech)'s YOLT-201 (for ATTR-PN/ATTR-CM) won clinical approval in March as [China's](/zh/entity/china) first LNP-mediated [in-vivo](/zh/entity/in-vivo-editing) gene-editing drug to enter trials, and two paediatric personalised CRISPR therapies are advancing. Chinese outlets frame the moves as proof of domestic depth in gene-editing-plus-cell-therapy platforms, paralleling [Intellia's](/zh/n/intellia-lonvo-z-invivo-crispr-bla-2026) Western filing.

## By the numbers

- 1st, claimed world-first in-brain CRISPR RNA-editing injection (Huida, MECP2 duplication).
- 2nd, globally, of CRISPR RNA-editing therapies to enter human testing.
- Mar 2026, YolTech YOLT-201 clinical approval (ATTR-PN/CM).
- 1st, China's first LNP-mediated in-vivo gene-editing drug in trials.
- 2, paediatric personalised CRISPR therapies advancing in 2026.

## Why it matters

China is fielding in-vivo gene edits roughly in step with US leaders, in a domestically-financed pipeline, while chip-export limits squeeze its AI-for-biology compute. In-brain CRISPR RNA editing is a frontier delivery claim that, if it holds, extends gene editing to the central nervous system, a target Western programs largely avoid.

## What to watch

- Peer-reviewed publication and durability of Huida's in-brain data.
- YolTech YOLT-201 trial progress and any NMPA approval timeline.
- Whether Chinese in-vivo programs file outside China (US/EU).

## Regional takes (batched by bias / lens)

### unlabelled
- **医药魔方 ByDrug** (China, zh) — Chinese pharma-data outlet's report on Huida Gene Therapeutics' clinical data for CRISPR RNA-editing therapy delivered directly into the human brain to treat MECP2 duplication syndrome, billed as a world first for in-brain CRISPR injection.
  Source: https://bydrug.pharmcube.com/news/detail/5b02bd9fb111cd078db47808fd3980d3
- **Innovative Genomics Institute (zh)** (United States, zh) — 
  Source: https://innovativegenomics.org/zh-CN/%E6%96%B0%E9%97%BB/crispr-%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C-2026/
- **ByDrug (CRISPR era)** (China, zh) — 
  Source: https://bydrug.pharmcube.com/news/detail/ab311d542ac5cfd1534f236242199ac2
- **CBPF China** (China, zh) — 
  Source: https://www.cbpfcn.com/news/4971
- **Innovative Genomics Institute (en)** (United States, en) — 
  Source: https://innovativegenomics.org/news/crispr-clinical-trials-2026/

### domestic pharma / capability
- **医药魔方 ByDrug (RNA editing)** (China, zh) — Domestic framing positions Huida's in-brain CRISPR RNA edit as a Chinese-led global first and the second CRISPR RNA-editing therapy worldwide to enter human testing, emphasising China's depth in gene-editing + cell-therapy and gene-editing + stem-cell platforms.
  > "全球首个脑内RNA疗法，实现CRISPR治疗历史性突破 (World's first in-brain RNA therapy, a historic CRISPR treatment breakthrough)."
  Source: https://bydrug.pharmcube.com/news/detail/5b02bd9fb111cd078db47808fd3980d3

### market outlook
- **搜狐 / Sohu (2026 biotech watch)** (China, zh) — Lists in-vivo gene editing among 2026's top biotech themes, noting YolTech's YOLT-201 (ATTR-PN/CM) won clinical approval in March as China's first LNP-mediated in-vivo gene-editing drug to enter trials, and two paediatric personalised CRISPR therapies advancing.
  > "2026年生物医药科技10大关注点 (Ten things to watch in biomedical tech in 2026)."
  Source: https://www.sohu.com/a/977744158_120319119

## Across the graph
- Related: [[intellia-lonvo-z-invivo-crispr-bla-2026]], [[smic-7nm-double-ascend-2026]]
- Entities: China, Crispr, Gene Editing, In Vivo Editing, Huida, Yoltech

---
Canonical: https://rbtfl.xyz/zh/n/china-invivo-gene-editing-2026